产品
编 号:F341430
分子式:C13H10N4O3
分子量:270.24
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
联系客服
产品详情
生物活性:
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM.

体内研究:
Ro 08-2750 (13.75 mg/kg; i.p.) inhibits leukemogenesis in a myeloid leukemia model in vivo.Animal Model:C57BL/6 wild type mice (10-12-weeks-old), MLL-AF9 murine leukemia model
Dosage:13.75?mg/kg
Administration:Intraperitoneal injection, at days 1, 4, 7, 10, and 13 (one day on, two days off drug)
Result:Inhibited c-MYC levels and reduced disease burden.

体外研究:
Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore.Ro 08-2750 (10 nM) completely rescues cells from undergoing NGF-induced SK-N-MC 103 cells death.Ro 08-2750 (5-10 μM; 8 hours) increases differentiation and apoptosis in myeloid leukemia cells.Ro 08-2750 inhibits survival of human AML lines and patient cells.Ro 08-2750 inhibits MSI2 RNA-binding and alters MSI2 gene signature.
产品资料